THOUSAND OAKS, Calif., Jan. 21, 2016 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that the Japanese Ministry of Health, Labour and Welfare has approved the cholesterol-lowering medication ...
(Reuters) - Amgen Inc , looking to boost use of its potent cholesterol drug Repatha, has cut the medication's U.S. list price by 60 percent to $5,850, the biotechnology company said on Wednesday.
The FINANCIAL — On July 21 Amgen announced that the European Commission (EC) has granted marketing authorization for Repatha (evolocumab), the first proprotein convertase subtilisin/kexin type 9 ...
To view the multimedia assets associated with this press release, please click: http://www.multivu.com/players/English/7414052-amgen-repatha/. The EC approved Repatha ...
Amgen is making Repatha (evolocumab), an innovative biologic medicine for people with high cholesterol who are at risk for heart attacks and strokes, available at a reduced list price of $5,850 per ...
The pharmaceutical company Amgen announced Wednesday that it will decrease the price of its cholesterol lowering drug Repatha by 60%. The company said some patients weren’t filling their prescriptions ...
SANTA MONICA, Calif., October 06, 2025--(BUSINESS WIRE)--GoodRx (Nasdaq: GDRX), the leading platform for medication savings in the U.S., today announced the availability of Repatha® (evolocumab), a ...
The maker of an expensive cholesterol drug is slashing the list price, which should make it more affordable for patients. Amgen Inc. said Wednesday it is immediately cutting the price of Repatha by 60 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback